Dose Escalation Trial of Denileukin Diftitox (Ontak) Post Autologous Transplantation



Status:Archived
Conditions:Blood Cancer, Hematology
Therapuetic Areas:Hematology, Oncology
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:November 2010

Use our guide to learn which trials are right for you!

Phase I Dose Escalation Trial of Denileukin Diftitox (Ontak) Post Autologous Transplantation.


The primary goal of this study is to determine the feasibility and safety of giving two
doses of denileukin diftitox (DD) at days 0 and 21 post autologous stem cell transplantation
in a dose escalation fashion. Secondary goals include evaluating the the effect of DD on the
number and percentage of T-regs in the peripheral blood post transplant at each dose level,
the effect of DD on T cell (CD4/CD8) reconstitution post transplant at each dose level and
determining the time to engraftment: absolute neutrophil count (>0.5 x 10^9/L for 3
consecutive days), and platelet (>20X 10^9/L for 3 consecutive days).

The hypothesis for the study is based on the ability of DD to deplete T-regs and
subsequently enhance the immune reconstitution and reverse post transplant lymphopenia. This
may indirectly enhance the efficacy of autologous transplantation and reduce disease
relapse.



We found this trial at
1
site
4201 St Antoine St
Detroit, Michigan 48201
(313) 577-1429
Wayne State University/Detroit Medical Center Founded in 1868, the Wayne State University School of Medicine...
?
mi
from
Detroit, MI
Click here to add this to my saved trials